Prudential Financial’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Prudential Financial’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-577	Closed	-$11K	–	2358
2016 Q1	$11K	Hold	577	–	–	﹤0.01%	2288
2015 Q4	$15K	Hold	577	–	–	﹤0.01%	2228
2015 Q3	$26K	Buy	577 +30	+5%	+$1.13K	﹤0.01%	2202
2015 Q2	$18K	Sell	547 -35	-6%	-$1.02K	﹤0.01%	2220
2015 Q1	$19K	Hold	582	–	–	﹤0.01%	2219
2014 Q4	$22K	Sell	582 -5	-0.9%	-$138	﹤0.01%	2186
2014 Q3	$15K	Sell	587 -591	-50%	-$15.6K	﹤0.01%	2208
2014 Q2	$35K	Buy	1,178 +666	+130%	+$21.5K	﹤0.01%	2399
2014 Q1	$19K	Sell	512 -5	-1%	-$190	﹤0.01%	2257
2013 Q4	$21K	Sell	517 -125	-19%	-$4.89K	﹤0.01%	2278
2013 Q3	$34K	Buy	642 +35	+6%	+$2.04K	﹤0.01%	2255
2013 Q2	$32K	Buy	+607	New	+$30.3K	﹤0.01%	2267

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Prudential Financial's NAVB Position: Q2 2016 in Review

Prudential Financial sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 577 shares — an estimated $11K sold.

Prudential Financial first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $35K in Q2 2014. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Prudential Financial reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Prudential Financial sold 577 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $11K.
Prudential Financial first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
Prudential Financial's Navidea Biopharmaceuticals Inc. position peaked at $35K in Q2 2014.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Prudential Financial's 13F filing for Q2 2016, filed 9 Aug 2016.